Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
REV3L antisense RNA 1 (REV3L-AS1) is a long non-coding RNA located antisense to the REV3L gene, which encodes the catalytic subunit of DNA polymerase zeta. The biological role of REV3L-AS1 has not been characterized in the literature, and it does not have documented involvement as a therapeutic target or disease biomarker. The majority of available research, both functional and translational, concerns the protein-coding REV3L gene and protein, which is essential for translesion DNA synthesis, chemoresistance, and maintenance of genome stability[1][2][3][5]. Note: If you are interested in the protein-coding gene (REV3L, DNA polymerase zeta catalytic subunit), there is extensive information available on its function, relevance in cancer chemoresistance, and potential as a drug target[1][2][3][4]. REV3L-AS1, as an lncRNA, currently lacks recognized biological function or clinical relevance in major databases and literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on REV3L antisense RNA 1 (REV3L-AS1).